Search Results

For the calibration of in-vitro diagnostic methods for the direct quantitative determination of HDL Cholesterol and LDL Cholesterol in serum.

DMA's HDL Cholesterol and LDL Cholesterol calibrator is intended for the calibration of in-vitro diagnostic methods for the direct quantitative determination of HDLC and LDLC in serum.

The provided document is a 510(k) summary for a medical device called "DMA HDL Cholesterol and LDL Cholesterol Calibrator." It describes the device's intended use and technological characteristics in comparison to a predicate device. However, this document does not contain any information regarding acceptance criteria, study details, performance metrics, sample sizes (for training or test sets), expert qualifications, or ground truth establishment relevant to the device's performance.

The document is a regulatory submission summarizing the device's purpose and its substantial equivalence to a predicate device for FDA clearance. It does not include the actual study data or the detailed acceptance criteria and performance results that would be part of a full study report.

Therefore, I cannot provide the requested information from this document.

Ask a specific question about this device

For the quantitative determination of Triglycerides in serum and plasma. Triglyceride measurements are used in the diagnosis and treatment of patients with diabetes mellitus, nephrosis, liver obstruction, other diseases involving lipid merabolism, or various endocrine disorders. Elevated serum triglyceride levels are seen in primary disorders of lipid metabolism or hyperlipoproteinemia secondary to known diseases. Furthermore, in conjunction with high-density lipoprotein and total serum cholesterol, a triglyceride determination provides valuable information for the assessment of coronary heart disease risk. The clinical significance and management of hyperlipoproteinemia depends on the triglyceride distribution among the major serum lipoproteins.

DMA's Triglyceride (GPO) Procedure is intended for in vitro diagnostic use for the quantitative determination of triglycerides in human serum or plasma. It is quite similar to many other assays which have long been used for this purpose.

The provided document describes the DMA's Triglyceride (GPO) Procedure, an in vitro diagnostic device for the quantitative determination of triglycerides in human serum or plasma.

Here's an analysis of its acceptance criteria and the study that proves the device meets them:

1. A table of acceptance criteria and the reported device performance

Note on Acceptance Criteria: The document does not explicitly state pre-defined acceptance criteria for each performance characteristic. Instead, it "has been shown to have the following performance characteristics". For a 510(k) submission, the comparison is often made against a predicate device, and the implicit acceptance criteria are that the new device's performance is comparable or non-inferior to the predicate.

2. Sample size used for the test set and the data provenance

The document does not explicitly state the sample size used for the test set or the data provenance (e.g., country of origin, retrospective or prospective). This level of detail is typically found in the full 510(k) submission, not the summary letter.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts

This information is not provided in the document. For an in vitro diagnostic device like this, "ground truth" for method performance characteristics (linearity, precision, sensitivity, interferences) is typically established through reference methods, certified calibrators, and control materials, rather than expert interpretation of results. Clinical correlation for "expected values" would involve studies with patient populations, but the details are not available here.

4. Adjudication method for the test set

This is not applicable to the type of performance characteristics described for this in vitro diagnostic device. Adjudication methods (like 2+1, 3+1) are typically used for studies involving expert interpretation of medical images or clinical outcomes, where there might be inter-reader variability.

5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

This is not applicable as the DMA Triglyceride (GPO) Procedure is an in vitro diagnostic assay for chemical analysis, not an AI-assisted diagnostic tool that would involve human readers interpreting output.

6. If a standalone (i.e. algorithm only without human-in-the loop performance) was done

This is not applicable. The device is a laboratory assay, not an algorithm, and its performance is inherently "standalone" in the sense that it produces a quantitative result directly. There isn't a human-in-the-loop component in the direct measurement process of this assay.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)

For the performance characteristics described:

• Linearity, Precision, Sensitivity: Ground truth is established using certified reference materials, calibrators, and control samples with known triglyceride concentrations, or comparisons against a recognized reference method.
• Interferences: Ground truth is established by spiking samples with known concentrations of interfering substances (bilirubin, hemoglobin) and observing the impact on triglyceride measurements compared to unspiked controls or reference methods.
• Expected Values: Ground truth for these values would typically come from clinical studies on specific populations to establish reference ranges, often derived statistically from a healthy population.

The document does not provide specifics on how these ground truths were established, only that the device "has been shown to have" these characteristics.

8. The sample size for the training set

The concept of a "training set" is primarily relevant for machine learning or AI models. This is an in vitro diagnostic assay, not an AI model, so there isn't a "training set" in that context. The development and optimization of the assay would involve various experiments and optimizations, but these are not referred to as "training sets."

9. How the ground truth for the training set was established

As there is no "training set" in the context of an AI/ML model for this device, this question is not applicable. The development of the assay would involve standard laboratory practices for developing and validating chemical assays.

Ask a specific question about this device

For in-vitro diagnostic use. For the quantitative determination of gamma glutamyltransferase in serum.

Elevated serum gamma glutamyltransferase (GGT) is found in chronic alcoholism, diabetes, certain neurological disorders, and all forms of liver disease. It is more sensitive than alkaline phosphatase, the transaminases, and leucine aminopeptidase (LAP) in detecting obstructive jaundice, cholangitis, and cholecystitis; its rise occurs earlier than these other enzymes and persists longer. Moderate increases are seen with infectious hepatitis, and normal levels are seen in skeletal disease. Serum GGT levels can therefore be used to differentiate skeletal or hepatobiliary disease.

The intended use is the same as the predicate device.

The method is based on the reaction wherein gamyl glutamyltransferase catalyzes the transfer of the glutamyl group from L-g-glutamyl-3-carboxy-4-nitroanilide to glycylglycine with the formation of g-glutamylglycylglycine and 5-amino-2-nitrobenzoate. The rate of increase of 5-amino-2-nitrobenzene, which absorbs light at 405 nM. is proportional to the gamma glutamyltransferase activity in the sample.

1. Acceptance Criteria and Reported Device Performance:

2. Sample Size and Data Provenance:

The provided text focuses on the performance characteristics of the device and its comparison to a predicate device. It does not explicitly state the sample sizes used for the testing of linearity, precision, sensitivity, or interference studies. The data provenance is also not specified (e.g., country of origin, retrospective or prospective).

3. Number and Qualifications of Experts for Ground Truth:

Not applicable. This is an in vitro diagnostic device for quantitative determination of an enzyme, not an imaging or diagnostic AI tool that requires expert interpretation for ground truth establishment.

4. Adjudication Method:

Not applicable. See point 3.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study:

Not applicable. This is not a comparative effectiveness study involving human readers and AI for diagnostic tasks. It's a comparison of an in vitro diagnostic assay to a predicate device.

6. Standalone Performance:

Yes, the provided data describes the standalone performance of the Data Medical Associates device through various non-clinical tests (linearity, precision, shelf-life, sensitivity, interferences, expected values). This data represents the performance of the algorithm/reagent without human intervention in the measurement process.

7. Type of Ground Truth Used:

The "ground truth" for the performance characteristics described here would be established through laboratory reference methods, calibrated standards, and known concentrations of analytes.

• Linearity: Determined by assaying samples with known, varying concentrations of GGT and ensuring the measured values are proportional.
• Precision: Determined by repeated measurements of samples with known GGT concentrations.
• Sensitivity: Determined by measuring the lowest detectable concentration of GGT using established methods.
• Interferences: Determined by spiking samples with known concentrations of potential interfering substances (bilirubin, hemoglobin, triglycerides) and observing their effect on GGT measurements compared to unspiked controls.
• Expected Values: Established through studies of a healthy reference population using validated methods.

8. Sample Size for the Training Set:

Not applicable. This is not a machine learning or AI-driven device in the sense of requiring a "training set." The device is a chemical reagent method.

9. How the Ground Truth for the Training Set was Established:

Not applicable. See point 8.

Ask a specific question about this device

Ask a specific question about this device

Ask a specific question about this device